Madrigal Pharmaceuticals Inc MDGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
-
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
-
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
-
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
-
Madrigal's stock surges as FDA approves first drug for liver disease MASH
-
Madrigal Shares Leap Premarket on First FDA NASH Green Light
-
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 289.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 376
- Website
- http://www.madrigalpharma.com
Comparables
Valuation
|
Metric
|
MDGL
|
TERN
|
TRVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.38 | 2.75 | 3.65 |
Price/Sales | 289.00 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MDGL
|
TERN
|
TRVI
|
|---|---|---|---|
Quick Ratio | 8.51 | 20.57 | 10.29 |
Current Ratio | 8.72 | 21.02 | 10.68 |
Interest Coverage | −35.43 | — | −4,780.89 |
Quick Ratio
MDGL
TERN
TRVI
Profitability
|
Metric
|
MDGL
|
TERN
|
TRVI
|
|---|---|---|---|
Return on Assets (Normalized) | −65.21% | −28.87% | −40.88% |
Return on Equity (Normalized) | −97.95% | −30.36% | −44.19% |
Return on Invested Capital (Normalized) | −81.63% | −34.37% | −48.62% |
Return on Assets
MDGL
TERN
TRVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xntfnfkhp | Kjq | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Llgxwxyjn | Tzbstf | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kzwtpxwh | Yjgcym | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lqdxjgqr | Qsjyrj | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Pywysprv | Zywy | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Zrqhsjkg | Lvh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wrsqcdpc | Pjky | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Tlryxkffk | Pnhx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sglmzqvg | Xqmpcmf | $13.4 Bil | |||
| Incyte Corp
INCY
| Wnytbshs | Fybjtpm | $12.7 Bil |
United States